Knockdown of flotillin-2 impairs the proliferation of breast cancer cells through modulation of Akt/FOXO signaling

Xie,Gui'e; Li,Jinlong; Chen,Jingsong; Tang,Xuewei; Wu,Shaoqing; Liao,Can

doi:10.3892/or.2015.3826

Knockdown of flotillin-2 impairs the proliferation of breast cancer cells through modulation of Akt/FOXO signaling

Authors:
- Gui'e Xie
- Jinlong Li
- Jingsong Chen
- Xuewei Tang
- Shaoqing Wu
- Can Liao
View Affiliations

Affiliations: Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510623, P.R. China, School of Biotechnology, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: March 3, 2015 https://doi.org/10.3892/or.2015.3826
Pages: 2285-2290

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lipid rafts, specialized domains in cell membranes, function as physical platforms for various molecules to coordinate a variety of signal transduction processes. Flotillin-2 (FLOT2), a marker of lipid rafts, is involved in the progression of cancer, yet the precise mechanism remains unclear. In the present study, we examined the effect of FLOT2 on cell proliferation and found that silencing endogenous FLOT2 with shRNAs inhibited proliferation of breast cancer cells. Furthermore, the antiproliferative effect of silencing FLOT2 on breast cancer cells was associated with upregulation of cyclin-dependent kinase (CDK) inhibitors p21Cip1 and p27Kip1. Moreover, we further demonstrated that the silencing of FLOT2 enhanced the transcriptional activity of FOXO factors by decreasing its phosphorylation through inhibiting the PI3K/Akt signaling pathway. Taken together, our results provide the ﬁrst demonstration of a novel mechanism by which FLOT2 induces proliferation of breast cancer cells, and our ﬁndings suggest that FLOT2 plays an important role in oncogenesis of breast cancer and thereby may be a potential target for human breast cancer treatment.

View Figures

View References

1	Friedenreich CM: Physical activity and breast cancer: Review of the epidemiologic evidence and biologic mechanisms. Recent Results Cancer Res. 188:125–139. 2011. View Article : Google Scholar : PubMed/NCBI
2	Zheng L, Zhou B, Meng X, Zhu W, Zuo A, Wang X, Jiang R and Yu S: A model of spontaneous mouse mammary tumor for human estrogen receptor- and progesterone receptor-negative breast cancer. Int J Oncol. 45:2241–2249. 2014.PubMed/NCBI
3	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
4	Guan Y, Song H, Zhang G and Ai X: Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma. Oncol Rep. 32:748–754. 2014.PubMed/NCBI
5	Babuke T and Tikkanen R: Dissecting the molecular function of reggie/flotillin proteins. Eur J Cell Biol. 86:525–532. 2007. View Article : Google Scholar : PubMed/NCBI
6	Lin C, Wu Z, Lin X, Yu C, Shi T, Zeng Y, Wang X, Li J and Song L: Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res. 17:3089–3099. 2011. View Article : Google Scholar : PubMed/NCBI
7	Langhorst MF, Reuter A and Stuermer CA: Scaffolding microdomains and beyond: The function of reggie/flotillin proteins. Cell Mol Life Sci. 62:2228–2240. 2005. View Article : Google Scholar : PubMed/NCBI
8	Hazarika P, McCarty MF, Prieto VG, George S, Babu D, Koul D, Bar-Eli M and Duvic M: Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res. 64:7361–7369. 2004. View Article : Google Scholar : PubMed/NCBI
9	Zhu Z, Wang J, Sun Z, Sun X, Wang Z and Xu H: Flotillin2 expression correlates with HER2 levels and poor prognosis in gastric cancer. PLoS One. 8:e623652013. View Article : Google Scholar : PubMed/NCBI
10	Rickman DS, Millon R, De Reynies A, Thomas E, Wasylyk C, Muller D, Abecassis J and Wasylyk B: Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene. 27:6607–6622. 2008. View Article : Google Scholar : PubMed/NCBI
11	Yan Y, Yang FQ, Zhang HM, Che J and Zheng JH: Up-regulation of flotillin-2 is associated with renal cell carcinoma progression. Tumour Biol. 35:10479–10486. 2014. View Article : Google Scholar : PubMed/NCBI
12	Wen Q, Li J, Wang W, et al: Increased expression of flotillin-2 protein as a novel biomarker for lymph node metastasis in nasopharyngeal carcinoma. PLoS One. 9:e1016762014. View Article : Google Scholar : PubMed/NCBI
13	Wang X, Yang Q, Guo L, Li XH, Zhao XH, Song LB and Lin HX: Flotillin-2 is associated with breast cancer progression and poor survival outcomes. J Transl Med. 11:1902013. View Article : Google Scholar : PubMed/NCBI
14	Pust S, Dyve AB, Torgersen ML, van Deurs B and Sandvig K: Interplay between toxin transport and flotillin localization. PLoS One. 5:e88442010. View Article : Google Scholar : PubMed/NCBI
15	Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, DeCaprio JA and Weinberg RA: Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 22:2111–2123. 2002. View Article : Google Scholar : PubMed/NCBI
16	Xie G, Tang H, Wu S, Chen J, Liu J and Liao C: The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo. Int J Oncol. 45:804–812. 2014.PubMed/NCBI
17	Xie G, Zhu X, Li Q, et al: SZ-685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the Akt/FOXO pathway. Br J Pharmacol. 159:689–697. 2010. View Article : Google Scholar : PubMed/NCBI
18	Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M and Sellers WR: Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 20:8969–8982. 2000. View Article : Google Scholar : PubMed/NCBI
19	Cardozo T and Pagano M: The SCF ubiquitin ligase: Insights into a molecular machine. Nat Rev Mol Cell Biol. 5:739–751. 2004. View Article : Google Scholar : PubMed/NCBI
20	Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
21	Burgering BM: A brief introduction to FOXOlogy. Oncogene. 27:2258–2262. 2008. View Article : Google Scholar : PubMed/NCBI
22	Yu W, Wang J, Ma L, Tang X, Qiao Y, Pan Q, Yu Y and Sun F: CD166 plays a pro-carcinogenic role in liver cancer cells via inhibition of FOXO proteins through AKT. Oncol Rep. 32:677–683. 2014.PubMed/NCBI
23	Doerfler W, Hohlweg U, Müller K, Remus R, Heller H and Hertz J: Foreign DNA integration - perturbations of the genome - oncogenesis. Ann NY Acad Sci. 945:276–288. 2001. View Article : Google Scholar
24	Arden KC: FoxOs in tumor suppression and stem cell maintenance. Cell. 128:235–237. 2007. View Article : Google Scholar : PubMed/NCBI
25	Park SH, Lee JH, Berek JS and Hu MC: Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. Int J Oncol. 45:1691–1698. 2014.PubMed/NCBI
26	Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM and Tindall DJ: Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA. 102:1649–1654. 2005. View Article : Google Scholar : PubMed/NCBI
27	Seoane J, Le HV, Shen L, Anderson SA and Massagué J: Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 117:211–223. 2004. View Article : Google Scholar : PubMed/NCBI